Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adipocytokine signaling pathway 💬
 1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
2 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
3 Alcoholic liver disease 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
4 Alcoholic liver disease 💬
 1件: C5AR1 💬 Avacopan 💬 Avacopan 3件: 43, 44, 222 💬
5 Allograft rejection 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
6 Allograft rejection 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
7 Allograft rejection 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
8 Antifolate resistance 💬
 2件: DHFR, DHFR2 💬 Methotrexate 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
9 Asthma 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
10 Asthma 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
11 Autoimmune thyroid disease 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
12 Autoimmune thyroid disease 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
13 Autoimmune thyroid disease 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
14 Biosynthesis of cofactors 💬
 2件: DHFR, DHFR2 💬 Methotrexate 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
15 Cell adhesion molecules 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
16 cGMP-PKG signaling pathway 💬
 1件: OPRD1 💬 Naltrexone 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
17 Chemical carcinogenesis - receptor activation 💬
 1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
18 Chemokine signaling pathway 💬
 2件: JAK2, JAK3 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
19 Cholinergic synapse 💬
 1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
20 Complement and coagulation cascades 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
21 Complement and coagulation cascades 💬
 1件: C5AR1 💬 Avacopan 💬 Avacopan 3件: 43, 44, 222 💬
22 Coronavirus disease - COVID-19 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
23 Coronavirus disease - COVID-19 💬
 1件: C5AR1 💬 Avacopan 💬 Avacopan 3件: 43, 44, 222 💬
24 Coronavirus disease - COVID-19 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
25 Coronavirus disease - COVID-19 💬
 2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
26 Cytokine-cytokine receptor interaction 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
27 Cytokine-cytokine receptor interaction 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
28 Cytokine-cytokine receptor interaction 💬
 1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
29 Cytokine-cytokine receptor interaction 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
30 Cytokine-cytokine receptor interaction 💬
 1件: TNFSF13B 💬 Belimumab 💬 Belimumab 13件: 11, 13, 43, 44, 46, 49, 51, 53, 63, 66, 222, 296, 300 💬
31 Drug metabolism - other enzymes 💬
 2件: IMPDH1, IMPDH2 💬 Mycophenolate mofetil 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
32 Drug metabolism - other enzymes 💬
 2件: IMPDH1, IMPDH2 💬 Mycophenolic acid 💬 Mycophenolic acid 36件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
33 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
34 EGFR tyrosine kinase inhibitor resistance 💬
 2件: JAK1, JAK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
35 Epstein-Barr virus infection 💬
 3件: JAK1, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
36 Estrogen signaling pathway 💬
 1件: OPRM1 💬 Naltrexone 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
37 Fc epsilon RI signaling pathway 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
38 Fc epsilon RI signaling pathway 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
39 Folate biosynthesis 💬
 2件: DHFR, DHFR2 💬 Methotrexate 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
40 Graft-versus-host disease 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
41 Growth hormone synthesis, secretion and action 💬
 1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
42 Hematopoietic cell lineage 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
43 Hematopoietic cell lineage 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
44 Hematopoietic cell lineage 💬
 1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
45 Hematopoietic cell lineage 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
46 Hematopoietic cell lineage 💬
 1件: MS4A1 💬 Obinutuzumab 💬 Obinutuzumab 4件: 43, 44, 49, 222 💬
47 Hematopoietic cell lineage 💬
 1件: MS4A1 💬 Rituximab 💬 Rituximab 48件: 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
48 Hepatitis B 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
49 Hepatitis C 💬
 2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
50 Herpes simplex virus 1 infection 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
51 Herpes simplex virus 1 infection 💬
 3件: JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
52 HIF-1 signaling pathway 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
53 Human cytomegalovirus infection 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
54 Human cytomegalovirus infection 💬
 1件: JAK1 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
55 Human papillomavirus infection 💬
 2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
56 Human T-cell leukemia virus 1 infection 💬
 2件: JAK1, JAK3 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
57 IL-17 signaling pathway 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
58 IL-17 signaling pathway 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
59 Inflammatory bowel disease 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
60 Inflammatory bowel disease 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
61 Influenza A 💬
 3件: JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
62 Intestinal immune network for IgA production 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
63 Intestinal immune network for IgA production 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
64 Intestinal immune network for IgA production 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
65 Intestinal immune network for IgA production 💬
 1件: TNFSF13B 💬 Belimumab 💬 Belimumab 13件: 11, 13, 43, 44, 46, 49, 51, 53, 63, 66, 222, 296, 300 💬
66 JAK-STAT signaling pathway 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
67 JAK-STAT signaling pathway 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
68 JAK-STAT signaling pathway 💬
 1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
69 JAK-STAT signaling pathway 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
70 JAK-STAT signaling pathway 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
71 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
72 Kaposi sarcoma-associated herpesvirus infection 💬
 3件: JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
73 Leishmaniasis 💬
 2件: JAK1, JAK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
74 Lipid and atherosclerosis 💬
 1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
75 Measles 💬
 3件: JAK1, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
76 Metabolic pathways 💬
 2件: DHFR, DHFR2 💬 Methotrexate 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
77 Metabolic pathways 💬
 2件: IMPDH1, IMPDH2 💬 Mycophenolate mofetil 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
78 Metabolic pathways 💬
 2件: IMPDH1, IMPDH2 💬 Mycophenolic acid 💬 Mycophenolic acid 36件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
79 Morphine addiction 💬
 1件: OPRM1 💬 Naltrexone 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
80 Necroptosis 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
81 Neuroactive ligand-receptor interaction 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
82 Neuroactive ligand-receptor interaction 💬
 1件: C5AR1 💬 Avacopan 💬 Avacopan 3件: 43, 44, 222 💬
83 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Prednisolone 💬 Prednisolone 42件:  3 , 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
84 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 Prednisone 💬 Prednisone 45件:  2 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 💬
85 Neuroactive ligand-receptor interaction 💬
 3件: OPRD1, OPRK1, OPRM1 💬 Naltrexone 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
86 Neutrophil extracellular trap formation 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
87 Neutrophil extracellular trap formation 💬
 1件: C5AR1 💬 Avacopan 💬 Avacopan 3件: 43, 44, 222 💬
88 NF-kappa B signaling pathway 💬
 1件: TNFSF13B 💬 Belimumab 💬 Belimumab 13件: 11, 13, 43, 44, 46, 49, 51, 53, 63, 66, 222, 296, 300 💬
89 NOD-like receptor signaling pathway 💬
 2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
90 Non-alcoholic fatty liver disease 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
91 Non-small cell lung cancer 💬
 1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
92 Nucleotide metabolism 💬
 2件: IMPDH1, IMPDH2 💬 Mycophenolate mofetil 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
93 Nucleotide metabolism 💬
 2件: IMPDH1, IMPDH2 💬 Mycophenolic acid 💬 Mycophenolic acid 36件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
94 One carbon pool by folate 💬
 2件: DHFR, DHFR2 💬 Methotrexate 💬 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
95 Osteoclast differentiation 💬
 2件: JAK1, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
96 Pancreatic cancer 💬
 1件: JAK1 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
97 Pathways in cancer 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
98 Pathways in cancer 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
99 Pathways in cancer 💬
 1件: IL5RA 💬 Benralizumab 💬 Benralizumab 5件: 44, 45, 98, 162, 299 💬
100 Pathways in cancer 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
101 Pathways in cancer 💬
 3件: JAK1, JAK2, JAK3 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
102 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: JAK1, JAK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
103 Pertussis 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
104 PI3K-Akt signaling pathway 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
105 PI3K-Akt signaling pathway 💬
 3件: JAK1, JAK2, JAK3 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
106 Primary immunodeficiency 💬
 1件: JAK3 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
107 Prion disease 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
108 Prolactin signaling pathway 💬
 1件: JAK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
109 Purine metabolism 💬
 2件: IMPDH1, IMPDH2 💬 Mycophenolate mofetil 💬 Mycophenolate mofetil 34件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
110 Purine metabolism 💬
 2件: IMPDH1, IMPDH2 💬 Mycophenolic acid 💬 Mycophenolic acid 36件:  2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
111 Regulation of actin cytoskeleton 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
112 Rheumatoid arthritis 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
113 Rheumatoid arthritis 💬
 1件: TNFSF13B 💬 Belimumab 💬 Belimumab 13件: 11, 13, 43, 44, 46, 49, 51, 53, 63, 66, 222, 296, 300 💬
114 Signaling pathways regulating pluripotency of stem cells 💬
 3件: JAK1, JAK2, JAK3 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
115 Sphingolipid signaling pathway 💬
 1件: OPRD1 💬 Naltrexone 💬 Naltrexone 13件:  6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
116 Staphylococcus aureus infection 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
117 Staphylococcus aureus infection 💬
 1件: C5AR1 💬 Avacopan 💬 Avacopan 3件: 43, 44, 222 💬
118 Systemic lupus erythematosus 💬
 1件: C5 💬 Vilobelimab 💬 Vilobelimab 3件: 43, 44, 269 💬
119 Systemic lupus erythematosus 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
120 T cell receptor signaling pathway 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
121 T cell receptor signaling pathway 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
122 Th1 and Th2 cell differentiation 💬
 1件: IL5 💬 Mepolizumab 💬 Mepolizumab 4件: 44, 45, 98, 162 💬
123 Th1 and Th2 cell differentiation 💬
 1件: IL5 💬 Reslizumab 💬 Reslizumab 2件: 44, 98 💬
124 Th1 and Th2 cell differentiation 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
125 Th17 cell differentiation 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
126 Th17 cell differentiation 💬
 4件: JAK1, JAK2, JAK3, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
127 Toll-like receptor signaling pathway 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
128 Toxoplasmosis 💬
 3件: JAK1, JAK2, TYK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
129 Transcriptional misregulation in cancer 💬
 1件: CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
130 Tuberculosis 💬
 2件: JAK1, JAK2 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
131 Type I diabetes mellitus 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
132 Viral carcinogenesis 💬
 2件: JAK1, JAK3 💬 Tofacitinib 💬 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
133 Viral myocarditis 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
134 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: IL6R 💬 Tocilizumab 💬 Tocilizumab 21件:  2 , 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
135 Virion - Adenovirus 💬
 2件: CD80, CD86 💬 Abatacept 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬

先頭へ